Calidi Biotherapeutics Inc [CLDI] stock prices are up 10.67% to $1.66 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CLDI shares have gain 5.06% over the last week, with a monthly amount glided 4.40%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Calidi Biotherapeutics Inc [AMEX: CLDI] stock has seen the most recent analyst activity on November 22, 2023, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $11. Previously, Robert W. Baird started tracking the stock with Outperform rating on October 09, 2023, and set its price target to $9.
The stock price of Calidi Biotherapeutics Inc [CLDI] has been fluctuating between $1.41 and $46.68 over the past year. Currently, Wall Street analysts expect the stock to reach $5.5 within the next 12 months. Calidi Biotherapeutics Inc [AMEX: CLDI] shares were valued at $1.66 at the most recent close of the market. An investor can expect a potential return of 231.33% based on the average CLDI price forecast.
Analyzing the CLDI fundamentals
Gross Profit Margin for this corporation currently stands at -0.29% with Operating Profit Margin at -13.28%, Pretax Profit Margin comes in at -13.32%, and Net Profit Margin reading is -13.2%. To continue investigating profitability, this company’s Return on Assets is posted at -2.12, Equity is 1804.73 and Total Capital is -5.0. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5233 points at the first support level, and at 1.3867 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7433, and for the 2nd resistance point, it is at 1.8267.
Ratios To Look Out For
It’s worth pointing out that Calidi Biotherapeutics Inc [AMEX:CLDI]’s Current Ratio is 1.13. On the other hand, the Quick Ratio is 1.13, and the Cash Ratio is 0.99.
Transactions by insiders
Recent insider trading involved Schoeneck James A, Director, that happened on Aug 21 ’25 when 75000.0 shares were purchased. Chief Executive Officer, Poma Eric E completed a deal on Aug 21 ’25 to buy 25000.0 shares. Meanwhile, Director Leftwich Scott bought 0.12 million shares on Aug 21 ’25.
